April 12, 2018 / 5:17 AM / 15 days ago

BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma

April 12 (Reuters) - ARGENX:

* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX

* AS PART OF AGREEMENT, ARGENX HAS GRANTED LEO PHARMA AN EXCLUSIVE OPTION TO OBTAIN A WORLDWIDE, EXCLUSIVE LICENSE TO ARGX-112 PROGRAM,

* ARGX-112 PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

* MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below